Резюме: Гречихина Мария Владимировна

Адрес

Федеральное государственное бюджетное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук, Москва, Россия

Контакты

https://www.ibch.ru/users/392

Работа в ИБХ

2005–наст.вр.	Младший научный сотрудник

Навыки

Работаю с культурами клеток с 2003 года, с большим количеством разных клеточных линий одновременно - с 2014 года. Составляю коллекцию клеточных линий, клетки для которой выращиваются по правилам клеточного банка, т е без антибиотиков и при максимально возможном исключении взаимной контаминации линий.

Также владею методами: проточная цитометрия, МТТ-тест, ИФА, измерение уровня АТФ при помощи хемилюминесценции.

Владение языками

русский, английский

Научные интересы

Иммунология, клеточные линии, банк клеток

Публикации

1. Palamarchuk AI, Ustiuzhanina MO, Velichinskii RA, Vavilova JD, **Grechikhina MV**, Kovalenko EI, Streltsova MA (2026). Interplay of telomerase non-canonical functions in NK cell resistance to iCasp9-mediated apoptosis. *Cell Death Discov* , , 10.1038/s41420-026-03183-y
2. Velichinskii RA, Streltsova MA, Vavilova JD, Boyko AA, Belovezhets TN, **Grechikhina MV**, Kovalenko EI (2025). PSCA-CAR-NK cells exert cytotoxic activity against PSCA-expressing tumor cells and are characterized by a specific chemokine profile. *Cytotherapy* 27 (12), 1384–1395, 10.1016/j.jcyt.2025.08.001
3. Shevchenko MA, Ovsyanikova OV, **Grechikhina MV**, Garbuz DG, Boyko AA, Evgenev MB, Zatsepina OG, Kovalenko EI, Sapozhnikov AM (2025). HSP70-NK and Target Cell Interactions: Implication to the Anticancer Effects. *Biochem (Mosc) Suppl Ser A Membr Cell Biol* 19 (1), 79–83, 10.1134/S1990747824700491
4. Streltsova MA, Boyko AA, Alekseeva NA, Proshkina GM, Shramova EI, **Grechikhina MV**, Shevchenko MA, Shustova OA, Popodko AI, Konovalova EV, Schulga AA, Sapozhnikov AM, Deyev SM, Kovalenko EI (2025). Genetically modified NK cells equipped with a switchable CAR for the treatment of HER2-positive cancers. *Biochimie* 238 (Pt B), 30–42, 10.1016/j.biochi.2025.07.021
5. Svirshchevskaya EV, Kostenko VV, Boyko AA, Shevtsov Ь, Kholodenko RV, **Grechikhina MV**, Gracheva IA, Fedorov AY, Sapozhnikov AM (2024). Core–Shell Chitosan Particles Targeting Membrane-Bound Heat Shock Protein 70 for Cancer Therapy. *Nanomaterials (Basel)* 14 (23), 1873, 10.3390/nano14231873
6. Alekseeva NA, Boyko AA, Shevchenko MA, **Grechikhina MV**, Streltsova MA, Alekseeva LG, Sapozhnikov AM, Deyev SM, Kovalenko EI (2024). Three-Dimensional Model Analysis Revealed Differential Cytotoxic Effects of the NK-92 Cell Line and Primary NK Cells on Breast and Ovarian Carcinoma Cell Lines Mediated by Variations in Receptor–Ligand Interactions and Soluble Factor Profiles. *Biomedicines* 12 (10), 2398, 10.3390/biomedicines12102398
7. Streltsova MA, Palamarchuk AI, Vavilova JD, Ustiuzhanina MO, Boyko AA, Velichinskii RA, Alekseeva NA,

Grechikhina MV, Shustova OA, Sapozhnikov AM, Kovalenko EI (2024). Methodological Approaches for Increasing the Retroviral Transduction Efficiency of Primary NK Cells. *Curr Pharm Des* 30 (37), 2947–2958, 10.2174/0113816128314633240724060916

8. Alekseeva LG, Ovsyanikova OV, Schulga AA, **Grechikhina MV**, Shustova OA, Kovalenko EI, Svirshchevskaya EV, Deyev SM, Sapozhnikov AM (2024). Targeted Delivery of HSP70 to Tumor Cells via Supramolecular Complex Based on HER2-Specific DARPin9_29 and the Barnase:Barstar Pair. *Cells* 13 (4), , 10.3390/cells13040317
9. Ovsyanikova OV, Shustova OA, **Grechikhina MV**, Sapozhnikov AM (2024). Flow cytometric analysis of the interaction of monoclonal antibodies to various epitopes of the HSP70 molecule with intracellular and membrane-associated forms of this protein. *Medical Immunology (Russia)* 26 (5), 905–912, 10.15789/1563-0625-FCA-16716
10. Kostenko VV, Boyko AA, **Grechikhina MV**, Ovsyanikova OV, Sapozhnikov AM (2024). Expression of membrane HSP70 on tumor cells during cultivation in 3D cultures. *Medical Immunology (Russia)* 26 (4), 657–662, 10.15789/1563-0625-EOM-16750
11. Alekseeva NA, Ustyuzhanina MO, Streltsova MA, **Grechikhina MV**, Lutsenko GV, Kovalenko EI (2023). NK CELL EXPANSION IN VITRO IS FOLLOWED BY LOSS OF INHIBITORY KIR EXPRESSION. *Medical Immunology (Russia)* 25 (3), 441–446, 10.15789/1563-0625-NCE-2845
12. Streltsova MA, Boyko AA, Ustiuzhanina MO, Palamarchuk AI, Alekseeva NA, Velichinskii RA, Vavilova JD, **Grechikhina MV**, Sapozhnikov AM, Deev SM, Kovalenko EI (2022). Subpopulation Heterogeneity of NK Cells during the Genetic Modification for Subsequent Use in Targeted Therapy. *Dokl Biochem Biophys* 507 (1), 380–382, 10.1134/S1607672922340142
13. Kalinovsky DV, Kibardin AV, Kholodenko IV, Svirshchevskaya EV, Doronin II, Konovalova MV, **Grechikhina MV**, Rozov FN, Larin SS, Deyev SM, Kholodenko RV (2022). Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors. *J Immunother Cancer* 10 (6), , 10.1136/jitc-2022-004646
14. Vavilova JD, Boyko AA, Troyanova NI, Ponomareva NV, Fokin VF, Fedotova EY, Streltsova MA, Kust SA, **Grechikhina MV**, Shustova OA, Azhikina TL, Kovalenko EI, Sapozhnikov AM (2022). Alterations in Proteostasis System Components in Peripheral Blood Mononuclear Cells in Parkinson Disease: Focusing on the HSP70 and p62 Levels. *Biomolecules* 12 (4), , 10.3390/biom12040493
15. Palamarchuk AI, Alekseeva NA, Streltsova MA, Ustiuzhanina MO, Kobyzeva PA, Kust SA, **Grechikhina MV**, Boyko AA, Shustova OA, Sapozhnikov AM, Kovalenko EI (2021). Increased susceptibility of the CD57− NK cells expressing KIR2DL2/3 and NKG2C to iCasp9 gene retroviral transduction and the relationships with proliferative potential, activation degree, and death induction response. *Int J Mol Sci* 22 (24), , 10.3390/ijms222413326
16. Vavilova JD, Boyko AA, Ponomareva NV, Fokin VF, Fedotova EY, Streltsova MA, Kust SA, **Grechikhina MV**, Bril EV, Zimnyakova OS, Kovalenko EI, Sapozhnikov AM (2021). Reduced Immunosenescence of Peripheral Blood T Cells in Parkinson's Disease with CMV Infection Background. *Int J Mol Sci* 22 (23), , 10.3390/ijms222313119
17. **(конференция)** Вавилова ЮД, Бойко АА, **Гречихина МВ**, Коваленко ЕИ, Сапожников АМ (2021). Phenotypic changes in peripheral blood Tlymphocytes in patients with Parkinson's disease. *FEBS Open Bio* , 463, 10.1002/2211-5463.13205
18. Erokhina SA, Streltsova MA, Kanevskiy LM, **Grechihina MV**, Sapozhnikov AM, Kovalenko EI (2020). HLA-DR-expressing NK cells: Effective killers suspected for antigen presentation. *J Leukoc Biol* 109 (2), 327–337, 10.1002/JLB.3RU0420-668RR
19. Malinovskaya YA, Kovalenko EI, Kovshova TS, Osipova NS, Maksimenko OO, Balabanyan VY, Razzhivina VA, **Grechikhina MV**, Boiko AA, Gelperina SE (2020). CYTOTOXICITY AND HEMOCOMPATIBILITY OF DOXORUBICIN-LOADED PLGA NANOPARTICLES. *РБЖ* 19 (1), 71–80, 10.17650/1726-9784-2019-19-1-71-80
20. Vavilova YD, Boyko AA, Kovalenko EI, **Grechikhina MV**, Shustova OA, Azhikina TL, Sapozhnikov AM (2020). Analysis of the association of the polymorphism of the CLIC1, MSH5, C6orf26, C6orf25 genes with the expression level of the HSPA1B gene. *Medical Immunology (Russia)* 22 (4), 779–784, 10.15789/1563-0625-AOT-1629
21. Svirshchevskaya E, Doronina E, **Grechikhina M**, Matushevskaya E, Kotsareva O, Fattakhova G,

Sapozhnikov A, Felix K (2019). Characteristics of multicellular tumor spheroids formed by pancreatic cells expressing different adhesion molecules. *Life Sci II* S0024 (19), 30048–7, 10.1016/j.lfs.2019.01.034

22. Streltsova MA, Erokhina SA, Kanevskiy LM, **Grechikhina MV**, Kobyzeva PA, Lee DA, Telford WG, Sapozhnikov AM, Kovalenko EI (2019). Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-γ Production, and Lifespan. *Int J Mol Sci* 20 (2), , 10.3390/ijms20020443
23. Kanevskiy LM, **Grechikhina MV**, Kuzmina EG, Mushkarina TY, Spelkov AA, Streltsova MA, Kovalenko EI (2019). Distribution of mica alleles in the Russian population. *Medical Immunology (Russia)* 21 (5), 959–964, 10.15789/1563-0625-2019-5-959-964
24. **(конференция)** Вавилова ЮД, Бойко АА, Шустова ОА, **Гречихина МВ**, Доронина ЕВ, Троянова НИ, Коваленко ЕИ, Сапожников АМ (2019). A comparative study of apoptosis in peripheral blood leukocytes in patients with Parkinson's disease and healthy donors. *Cell Death Discov* , , https://doi.org/10.1038/s41420-018-0128-4
25. Sapozhnikov AM, Klinkova AV, Shustova OA, **Grechikhina MV**, Kilyachus MS, Stremovskiy OA, Kovalenko EI, Deyev SM (2018). A Novel Approach to Anticancer Therapy: Molecular Modules Based on the Barnase:Barstar Pair for Targeted Delivery of HSP70 to Tumor Cells. *Acta Naturae* 10 (3), 85–91, 10.32607/20758251-2018-10-3-85-91
26. Lutsenko GV, **Grechikhina MV**, Efremov MA (2018). Autocrine Survival Factors of a Cytotoxic CTLL-2 Cell Line. *Biochem (Mosc) Suppl Ser A Membr Cell Biol* 12 (3), 239–246, 10.1134/S1990747818030066
27. Lutsenko GV, **Grechikhina MV**, Efremov MA (2018). Survival autocrine factors of cytotoxic cell line CTLL-2. *BIOL MEMBRANY* 35 (4), 271–279, 10.1134/S0233475518040096
28. Koloskova OO, Gileva AM, Drozdova MG, **Grechihina MV**, Suzina NE, Budanova UA, Sebyakin YL, Kudlay DA, Shilovskiy IP, Sapozhnikov AM, Kovalenko EI, Markvicheva EA, Khaitov MR (2018). Effect of lipopeptide structure on gene delivery system properties: Evaluation in 2D and 3D in vitro models. *Colloids Surf B Biointerfaces* 167, 328–336, 10.1016/j.colsurfb.2018.04.003
29. Konovalova M, Shagdarova B, Zubareva A, Generalov A, **Grechikhina M**, Svirshchevskaya E (2018). Development of mucoadhesive Chitosan-based drug delivery system. *Prog Chem Appl Chitin Deriv* 23, 103–113, 10.15259/PCACD.23.10
30. Svirshchevskaya EV, Zubareva AA, Boyko AA, Shustova OA, **Grechikhina MV**, Shagdarova BT, Varlamov VP (2016). Analysis of toxicity and biocompatibility of chitosan derivatives with different physico-chemical properties. *APPL BIOCHEM MICRO+* 52 (5), 483–490, 10.1134/S000368381605015X
31. Belova OV, Sergienko VI, Arion VY, Lukanidina TA, Moskvina SN, Zimina IV, Borisenko GG, Lutsenko GV, **Grechikhina MV**, Kovaleva EV, Klyuchnikova ZI (2014). Purification of high-molecular-weight subfraction from porcine skin inhibiting proliferation of A431 human carcinoma epidermoid cells. *Bull Exp Biol Med* 157 (3), 371–374, 10.1007/s10517-014-2569-y
32. Kovalenko EI, Boyko AA, Semenkov VF, Lutsenko GV, **Grechikhina MV**, Kanevskiy LM, Azhikina TL, Telford WG, Sapozhnikov AM (2014). ROS production, intracellular HSP70 levels and their relationship in human neutrophils: Effects of age. *Oncotarget* 5 (23), 11800–11812, 10.18632/oncotarget.2856
33. Lutsenko GV, **Grechikhina MV**, Diachkova LG, Sapozhnikov AM (2013). Protective action of autocrine factors of cytotoxic T lymphocytes under chemical hypoxia conditions. *Immunologiya* 34 (5), 251–254.
34. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ, Сапожников АМ (2013). Протективное действие аутокринных факторов цитотоксических Т-лимфоцитов в условиях химической гипоксии. 34 (5), 251–254.
35. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ (2009). О влиянии дефицита аутокринных факторов в культуре на протекание апоптоза в цитотоксических Т-клетках. 30 (1), 4–7.
36. Lutsenko GV, **Grechikhina MV**, Diachkova LG, Lutsan NI (2008). T-lymphocyte survival under conditions of alkalosis and autocrine factor deficiency. *BIOL MEMBRANY* 25 (6), 463–471.
37. Lutsenko GV, **Grechikhina MV**, Diachkova LG, Lutsan NI (2008). Survival of T-lymphocytes under alkalosis and autocrine factor deficiency. *Biochem (Mosc) Suppl Ser A Membr Cell Biol* 2 (4), 318–325, 10.1134/S1990747808040041
38. Lutsenko GV, **Grechikhina MV**, Diachkova LG (2008). Autocrine factor participation in defence of cytotoxic CTLL-2 cells from oxidative stress. *Tsitologiia* 50 (6), 492–499.
39. Lutsenko GV, **Grechikhina MV**, Diachkova LG (2008). Autocrine factors in defense of cytotoxic CTLL-2 cells

from oxidative stress. *Cell tissue biol* 2 (3), 239–245, 10.1134/S1990519X08030048
40. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ, Луцан НИ (2008). О выживании Т-лимфоцитов в условиях алкалоза и дефицита аутокринных факторов. 25 (6), 463–471.
41. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ (2008). Участие аутокринных факторов в защите клеток цитотоксической линии CTLL-2 от окислительного стресса. 50 (6), 492–499.
42. Lutsenko GV, **Grechikhina MV**, Diachkova LG, Lutsan NI (2007). Influence of autocrine factor deficit in culture on survival and energy metabolism of CTLL-2 cells under oxidative stress. *Tsitologiia* 49 (4), 284–291.
43. Lutsenko GV, **Grechikhina M**, Dyachkova LG, Lutsan NI (2007). Effects of an autocrine factor deficit on the survival and energy metabolism of CTLL-2 cells under oxidative stress conditions in culture. *Cell tissue biol* 1 (3), 235–243, 10.1134/S1990519X07030054
44. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ, Луцан НИ (2007). Влияние дефицита аутокринных факторов в культуре на выживание и энергетический метаболизм клеток линии CTLL-2 в условиях окислительного стресса. 49 (4), 284–291.
45. Луценко ГВ, **Гречихина МВ**, Дьячкова ЛГ (2005). Регуляция уровня АТФ в нормальных и трансформированных Т-клетках аутокринными факторами. 26, 91–95.